Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11
|
作者：
Tamburini, J. [1 ]
Elie, C. [2 ]
Park, S. [1 ]
Beyne-Rauzy, O. [3 ]
Gardembas, M. [4 ]
Berthou, C. [5 ]
Mahe, B. [6 ]
Sanhes, L. [7 ]
Stamatoullas, A. [8 ]
Vey, N. [9 ]
Aouba, A.
Slama, B. [10 ]
Quesnel, B. [11 ]
Vekhoff, A. [13 ]
Sotto, J. J. [12 ]
Vassilief, D. [1 ]
Al-Nawakil, C. [1 ]
Fenaux, P. [14 ]
Dreyfus, F. [1 ]
Bouscary, D. [1 ]
机构：
[1] Hop Cochin, Dept Haematol, Paris, France
[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France
[3] Hop Purpan, Dept Hematol Odile, Toulouse, France
[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France
[5] Hop Brest, Dept Hematol Christian, Brest, France
[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France
[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France
[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France
[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France
[11] Ctr Hosp Lille, Dept Hematol, Lille, France
[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France
[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France
[14] Hop Avicenne, Dept Hematol, Bobigny, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;
D O I：
10.1016/j.leukres.2008.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：547 / 550
页数：4
相关论文
共 50 条
  • [21] Repeated Hematocrit measurements in low-risk pregnant women
    Bailit, Jennifer L.
    Doty, Elizabeth
    Todia, William
    JOURNAL OF REPRODUCTIVE MEDICINE, 2007, 52 (07) : 619 - 622
  • [22] High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution
    Azzara, Antonio
    Carulli, Giovanni
    Galimberti, Sara
    Barate, Claudia
    Fazzi, Rita
    Cervetti, Giulia
    Petrini, Mario
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (09) : 762 - 767
  • [23] Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3trial
    Diez-Campelo, Maria
    Lopez-Cadenas, Felix
    Xicoy, Blanca
    Lumbreras, Eva
    Gonzalez, Teresa
    Gonzalez, Monica del Rey
    Sanchez-Garcia, Joaquin
    Jorda, Rosa Coll
    Slama, Bohrane
    Hernandez-Rivas, Jose-angel
    Thepot, Sylvain
    Bernal, Teresa
    Guerci-Bresler, Agnes
    Bargay, Joan
    Amigo, Maria Luz
    Preudhomme, Claude
    Fenwarth, Laurene
    Platzbecker, Uwe
    Goetze, Katharina S.
    Arar, Ali
    Toribio, Sofia
    Del Canizo, Consuelo
    Hernandez-Rivas, Jesus Maria
    Fenaux, Pierre
    LANCET HAEMATOLOGY, 2024, 11 (09): : e659 - e670
  • [24] Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa
    Jonasova, Anna
    Sotakova, Slavka
    Belohlavkova, Petra
    Minarik, Lubomir
    Stopka, Tomas
    Jonas, Jan Jakub
    Aghova, Tatiana
    Zemanova, Zuzana
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] Outcomes associated with transfusion in low-risk women with obstetric haemorrhage
    Patterson, Jillian A.
    Nippita, Tanya A.
    Randall, Deborah
    Irving, David O.
    Ford, Jane B.
    VOX SANGUINIS, 2018, 113 (07) : 678 - 685
  • [26] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [27] Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes
    Roberts, Daniel A.
    Wadleigh, Martha
    McDonnell, Anne M.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Steensma, David P.
    LEUKEMIA RESEARCH, 2015, 39 (02) : 204 - 210
  • [28] Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome
    Orhan, Bedrettin
    Nazlioglu, Hulya Ozturk
    Dik, Oguzhan
    Gurbuz, Busra
    Ozkocaman, Vildan
    Ersal, Tuba
    Pinar, Ibrahim Ethem
    Yalcin, Cumali
    Cubukcu, Sinem
    Koca, Tuba Gullu
    Hunutlu, Fazil cagri
    Yavuz, Seyma
    Ali, Ridvan
    Ozkalemkas, Fahir
    BIOMOLECULES AND BIOMEDICINE, 2025, : 1175 - 1183
  • [29] Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond - 9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004
    Fenaux, P.
    Bennett, J. M.
    Bowen, D. T.
    Knight, R. D.
    List, A. F.
    TRANSFUSION MEDICINE, 2007, 17 (03) : 151 - 160
  • [30] Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
    Oliva, Esther N.
    Alati, Caterina
    Santini, Valeria
    Poloni, Antonella
    Molteni, Alfredo
    Niscola, Pasquale
    Salvi, Flavia
    Sanpaolo, Grazia
    Balleari, Enrico
    Germing, Ulrich
    Fenaux, Pierre
    Stamatoullas, Aspasia
    Palumbo, Giuseppe A.
    Salutari, Prassede
    Impera, Stefana
    Avanzini, Paolo
    Cortelezzi, Agostino
    Liberati, Anna Marina
    Carluccio, Paola
    Buccisano, Francesco
    Voso, Maria Teresa
    Mancini, Stefano
    Kulasekararaj, Austin
    Morabito, Fortunato
    Bocchia, Monica
    Cufari, Patrizia
    Spiriti, Maria Antonietta Aloe
    Santacaterina, Irene
    D'Errigo, Maria Grazia
    Bova, Irene
    Zini, Gina
    Latagliata, Roberto
    LANCET HAEMATOLOGY, 2017, 4 (03): : E127 - E136
12345